KR101771692B1 - Composition for Preventing, Treating or Improving Menopausal Syndrome comprising Sparassis crispa Wulf.: Fr. and Lactic Acid Bacteria as Active Ingredient - Google Patents
Composition for Preventing, Treating or Improving Menopausal Syndrome comprising Sparassis crispa Wulf.: Fr. and Lactic Acid Bacteria as Active Ingredient Download PDFInfo
- Publication number
- KR101771692B1 KR101771692B1 KR1020150124824A KR20150124824A KR101771692B1 KR 101771692 B1 KR101771692 B1 KR 101771692B1 KR 1020150124824 A KR1020150124824 A KR 1020150124824A KR 20150124824 A KR20150124824 A KR 20150124824A KR 101771692 B1 KR101771692 B1 KR 101771692B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- menopausal
- mushroom
- symptoms
- control group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 206010027304 Menopausal symptoms Diseases 0.000 title claims abstract description 30
- 239000004480 active ingredient Substances 0.000 title claims abstract description 13
- 241000272503 Sparassis radicata Species 0.000 title claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title abstract description 96
- 241000894006 Bacteria Species 0.000 title abstract description 48
- 239000004310 lactic acid Substances 0.000 title abstract description 48
- 235000014655 lactic acid Nutrition 0.000 title abstract description 48
- 235000013305 food Nutrition 0.000 claims abstract description 24
- 208000024891 symptom Diseases 0.000 claims abstract description 17
- 230000007423 decrease Effects 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 210000001596 intra-abdominal fat Anatomy 0.000 claims abstract description 7
- 230000037182 bone density Effects 0.000 claims abstract description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 206010022489 Insulin Resistance Diseases 0.000 claims description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 11
- 208000001132 Osteoporosis Diseases 0.000 claims description 9
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 8
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 8
- 235000019786 weight gain Nutrition 0.000 claims description 8
- 230000004584 weight gain Effects 0.000 claims description 6
- 238000008214 LDL Cholesterol Methods 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 208000021017 Weight Gain Diseases 0.000 claims 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 abstract description 74
- 230000037396 body weight Effects 0.000 abstract description 10
- 238000005265 energy consumption Methods 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 241000186660 Lactobacillus Species 0.000 description 34
- 229940039696 lactobacillus Drugs 0.000 description 34
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 27
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 27
- 239000008103 glucose Substances 0.000 description 26
- 241000700159 Rattus Species 0.000 description 21
- 239000013641 positive control Substances 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 18
- 229920002498 Beta-glucan Polymers 0.000 description 15
- 102000004877 Insulin Human genes 0.000 description 15
- 108090001061 Insulin Proteins 0.000 description 15
- 229940125396 insulin Drugs 0.000 description 15
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 14
- 239000000262 estrogen Substances 0.000 description 13
- 229940011871 estrogen Drugs 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 239000000284 extract Substances 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 241000223960 Plasmodium falciparum Species 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 241000186000 Bifidobacterium Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 210000004197 pelvis Anatomy 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000007410 oral glucose tolerance test Methods 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241001608472 Bifidobacterium longum Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 240000008620 Fagopyrum esculentum Species 0.000 description 3
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 3
- 241000192132 Leuconostoc Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940009291 bifidobacterium longum Drugs 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 235000007882 dietary composition Nutrition 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- ZPVFWPFBNIEHGJ-UHFFFAOYSA-N 2-octanone Chemical compound CCCCCCC(C)=O ZPVFWPFBNIEHGJ-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 240000003296 Petasites japonicus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000949456 Zanthoxylum Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003075 phytoestrogen Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- SQCZQTSHSZLZIQ-UHFFFAOYSA-N 1-chloropentane Chemical compound CCCCCCl SQCZQTSHSZLZIQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical group CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 244000251953 Agaricus brunnescens Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000186715 Lactobacillus alimentarius Species 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- 235000002262 Lycopersicon Nutrition 0.000 description 1
- 241000227653 Lycopersicon Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241001489192 Pichia kluyveri Species 0.000 description 1
- 240000001462 Pleurotus ostreatus Species 0.000 description 1
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000123241 Sparassis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000003307 Zinnia violacea Species 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- -1 fluoroalkane Chemical compound 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 150000002305 glucosylceramides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- VSMOENVRRABVKN-UHFFFAOYSA-N oct-1-en-3-ol Chemical compound CCCCCC(O)C=C VSMOENVRRABVKN-UHFFFAOYSA-N 0.000 description 1
- NMRPBPVERJPACX-UHFFFAOYSA-N octan-3-ol Chemical compound CCCCCC(O)CC NMRPBPVERJPACX-UHFFFAOYSA-N 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000007780 powder milling Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A23Y2220/35—
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention provides a food composition and a pharmaceutical composition for preventing, ameliorating, or treating the symptoms of menopausal or menopausal symptoms, which comprises the mushroom and the lactic acid bacterium as an active ingredient. The composition of the present invention can effectively prevent, ameliorate, and treat various symptoms appearing in menopausal or menopausal period by suppressing increase in skin temperature, increase in body weight and visceral fat, decrease in bone density, and increase in energy consumption in postmenopausal period . The composition of the present invention can be applied to foods and medicines for preventing, ameliorating and treating menopausal symptoms or menopausal symptoms of women.
Description
The present invention relates to a composition for preventing, treating or ameliorating symptoms of menopausal or menopausal symptoms, which comprises an effective ingredient of P. falciparum and Lactobacillus.
Over the last 25 years, the importance of middle-aged social, emotional, and physical changes has been raised for long-term health and well-being of women. Various diseases in postmenopausal women are associated with estrogen deprivation, affecting their life expectancy and quality of life. The estrogen deficiency worsens energy, glucose, lipid and bone metabolism associated with metabolic diseases such as obesity,
Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.
The present inventors have sought to develop a phytoestrogen, which has the efficacy of an estrogen replacement agent for use in hormone replacement therapy for menopausal women, from a natural source. As a result, the present inventors have completed the present invention by experimentally confirming that the combination of P. japonicus and Lactobacillus have remarkably improved menopausal symptom alleviating effect as compared with a single substance of P. aeruginosa or Lactobacillus.
Accordingly, an object of the present invention is to provide a food composition for preventing or ameliorating symptoms of menopausal or menopausal symptoms, which comprises an effective ingredient of P. falciparum and Lactobacillus.
Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of menopausal symptoms or menopausal symptoms, which comprises an effective ingredient of P. falciparum and Lactobacillus.
Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention and claims.
According to one aspect of the present invention, there is provided a food composition for preventing or ameliorating symptoms of menopausal or menopausal symptoms comprising an effective ingredient of P. falciparum and Lactobacillus.
According to another aspect of the present invention, there is provided a pharmaceutical composition for the prevention or treatment of symptoms of menopausal or menopausal symptoms comprising an effective ingredient of P. falciparum and Lactobacillus.
The present inventors have sought to develop phytoestrogen, which has the efficacy of an estrogen replacement agent used in hormone replacement therapy for menopausal women, from natural products. As a result, it was experimentally confirmed that the combination of the mushroom and the lactic acid bacteria has a remarkably improved menopausal symptom alleviating effect as compared with the single substance of the mushroom or the lactic acid bacterium.
According to the present invention, when the mixture of the mushroom of the present invention and the mixture of lactic acid bacteria is fed to rats induced by menopause by ovariectomy, the increase of skin temperature is inhibited, the increase in body weight and visceral fat is suppressed, Increased consumption, reduced bone mineral density caused by menopause, reduced insulin resistance, increased HDL cholesterol and decreased LDL cholesterol. From these effects, the composition of the present invention can effectively prevent, ameliorate, and treat various symptoms appearing in menopausal period or menopausal period, and can be used as a health functional food and a pharmaceutical composition.
The sparassis used in the present invention crispa Wulf .: Fr.) refers to a wood-borne fungus belonging to the family Mycobacterium that grows like cabbage in the vicinity of the live tree root or stump of softwood between summer and fall.
According to one embodiment of the present invention, the blossom mushroom used in the composition of the present invention is powdery mushroom itself.
According to another embodiment of the present invention, the mushroom used in the composition of the present invention is produced by a conventional method known in the art for extracting an extract from a natural product, that is, a conventional solvent under the conditions of ordinary temperature and pressure May be an extract which has been separated by use.
In the case of extracting the mushroom extract used in the composition of the present invention by treating the mushroom with an extractant, various extraction solvents may be used. Preferably, a polar solvent or a non-polar solvent can be used. Suitable polar solvents are (i) water, (ii) alcohols (preferably methanol, ethanol, propanol, butanol, n-propanol, iso-propanol, n-butanol, 1-pentanol, , Ethylene glycol or butylene glycol), (iii) acetic acid, (iv) dimethyl-formamide (DMFO) and (v) dimethyl sulfoxide (DMSO). Suitable nonpolar solvents are acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1- But are not limited to, pentane, 1-chlorobutane, 1-chloropentane, o -xylene, diisopropyl ether, 2- chloropropane, toluene, 1- chloropropane, chlorobenzene, benzene, diethyl ether, diethylsulfide, Methane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride, and THF.
As used herein, the term " extract " has the meaning conventionally used in the art as a crude extract, but broadly includes fractions obtained by further fractionation of the extract. That is, the extract of Zygomycorrhizae mushroom is obtained not only by using the above-mentioned extraction solvent but also by additionally applying a purification process thereto. For example, a fraction obtained by passing the above extract through an ultrafiltration membrane having a constant molecular weight cut-off value, and a separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) The fraction obtained by the purification method is also included in the extract of the present invention.
According to the present invention, the granular mushroom used in the composition of the present invention can be obtained by treating the granular mushroom with a suitable solvent, and then obtaining the granular mushroom extract by powder milling in an additional process such as vacuum distillation, freeze-drying or spray drying have.
Lactic acid bacteria suitable for the present invention include various lactic acid bacteria known in the art. As used herein, the term " lactic acid bacteria " refers to a group of bacteria that produce lactic acid as a major product of carbohydrate metabolism. Preferably, the lactic acid bacteria used in the present invention are selected from the group consisting of Lactobacillus , Lactococcus , Leuconostoc , Propionibacterium , Enterococcus , Bifidobacterium Bifidobacterium , Streptococcus , and Pediococcus . More preferably, the lactic acid bacteria used in the present invention are selected from the group consisting of Lactobacillus fermentum , Lactobacillus alimentarius , Lactobacillus sakei , Lactobacillus acidophilus , Lactobacillus casei , Lactobacillus gasseri , Lactobacillus delbrueckii , Lactobacillus bulgaricus , Lactobacillus helveticus , Leuconostoc spp ., Lactobacillus spp ., Lactobacillus spp ., Lactobacillus spp . Leuconostoc mensenteroides , Streptococcus thermophilus , Streptococcus lactis , Enterococcus, faecium ), Enterococcus faecalis faecalis), Bifidobacterium William BP bonus (Bifidobacterium bifidum), Bifidobacterium William Infante Tees (Bifidobacterium infantis , Bifidobacterium brave , and Bifidobacterium longum . Bifidobacterium longum is a lactic acid bacterium selected from the group consisting of Bifidobacterium brave , Bifidobacterium brave , and Bifidobacterium longum . Most preferred is Lactobacillus fermentum .
The 'mixture of mushroom and lactic acid bacteria' used as an active ingredient in the present invention is a mixture of powdery mushroom powder and lactobacillus fermentum powder as a lactic acid bacterium, preferably a mixture of powdery mushroom powder and lactobacillus fermentum powder at a ratio of 15: 1 .
As used herein, the term " comprising as an active ingredient " is meant to include an amount sufficient to achieve efficacy or activity of a mixture of Mushroom and Lactic acid bacteria. The present invention is a composition derived from a natural plant material, such as Zanthoxylum mushroom and Lactobacillus acidus, which has no adverse effect on the human body even when administered in an excessive amount. Therefore, the quantitative upper limit of the composition of the present invention is determined by those skilled in the art .
As used herein, the term " menopausal or menopausal symptoms " refers to symptoms resulting from a decrease in hormone production in postmenopausal women, and menopausal or menopausal symptoms generally include facial flushing, sweating, The present invention relates to the use of a compound of the present invention for the manufacture of a medicament for use in the treatment of a disorder or condition selected from the group consisting of atopic dermatitis, Depression, loss of libido, myalgia, penetration, diabetes, or osteoporosis.
The food composition of the present invention includes all natural forms of processing such as food, functional food, nutritional supplement, health food, and food additives. Food compositions of this type may be prepared in a variety of forms according to conventional methods known in the art.
For example, as a health food, the mushroom and the lactic acid bacterium itself may be prepared in the form of tea, juice, and drink, and may be ingested, granulated, encapsulated and powdered. In addition, the composition of the present invention can be prepared by mixing together the known active ingredients known to have the effect of preventing or ameliorating diseases or symptoms caused by the mushroom and lactic acid bacteria of the present invention and menopausal period.
Foods also include beverages (including alcoholic beverages), fruits and processed foods (such as canned fruits, bottles, jams, maal malaysia, etc.), fish, meat and processed foods such as ham, sausage, ), Breads and noodles (eg udon, buckwheat noodles, ramen noodles, spaghetti, macaroni, etc.), juice, various drinks, cookies, sugar, dairy products such as butter, cheese, edible vegetable oil, margarine, vegetable protein, It can be produced by adding buckwheat or buckwheat sprout extract to foods, frozen foods, various seasonings (eg, soybean paste, soy sauce, sauces, etc.). In order to use the mushroom of the present invention and the lactic acid bacterium in the form of a food additive, it may be prepared in the form of a powder or a concentrated liquid.
In the food composition of the present invention, the preferred content of the mushroom and the lactic acid bacterium may be 0.001 to 50% by weight, preferably 0.1 to 30% by weight, based on the total weight of the food composition.
The pharmaceutical compositions according to the present invention may further comprise a pharmaceutically effective amount of Zanthoxylum mushroom and Lactobacillus acid alone or in combination with one or more pharmaceutically acceptable carriers, excipients or diluents.
The term " pharmaceutically acceptable " as used herein means a non-toxic composition which is physiologically acceptable and which, when administered to humans, does not inhibit the action of the active ingredient and does not normally cause an allergic reaction such as gastrointestinal disorder, dizziness, .
Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. The pharmaceutical composition may further include a filler, an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifier, and an antiseptic agent.
The term " pharmaceutically effective amount " as used herein refers to an amount that exhibits a higher level of response than the negative control, and preferably refers to an amount sufficient to exhibit the effect of preventing or treating a disease or symptom caused by menopause. The pharmacologically effective amount of the mushroom of the present invention and the lactic acid bacterium is 0.01 to 100 mg / day / kg body weight. However, the pharmaceutically effective amount may be appropriately changed depending on various factors such as the type and severity of the disease, the age, body weight, health condition, sex, administration route and treatment period of the patient.
In addition, the pharmaceutical composition of the present invention may be formulated using methods known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to the mammal. The formulations may be in the form of powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatine capsules, sterile injectable solutions, sterile powders.
The administration route of the composition of the present invention is not limited thereto, but it can be administered orally or parenterally. Parenteral routes of administration include, for example, various routes such as transdermal, nasal, peritoneal, muscular, subcutaneous or intravenous.
The pharmaceutical composition of the present invention may be administered in combination with a known compound having an effect of preventing or treating a disease or symptom related to menopausal or menopausal period.
As described above, the mixture of the mushroom and the lactic acid bacteria of the present invention can be usefully applied to foods and medicines for the prevention, improvement and treatment of menopausal symptoms of menopausal women.
The features and advantages of the present invention are summarized as follows:
(I) The present invention provides a food composition and a pharmaceutical composition for preventing, ameliorating or treating the symptoms of menopausal or menopausal symptoms, which comprises the mushroom and the lactic acid bacterium as an active ingredient.
(Ii) The composition of the present invention exhibits effects such as increase in skin temperature, increase in body weight and visceral fat in the menopausal period, decrease in bone density and increase of energy consumption, thereby effectively preventing, improving and improving various symptoms appearing in menopausal or menopausal period Can be treated.
(Iii) The composition of the present invention may be usefully applied to foods and medicines for preventing, ameliorating and treating menopausal symptoms of menopausal women.
1 is a structural formula of beta-glucan.
2 is a schematic diagram showing an experimental schedule.
Fig. 3 is a graph showing changes in tail skin temperature (a) and average value (b) of an experimental animal.
FIG. 4 shows the results of measurement of body weight gain (a) and body fat mass (b) in the experimental animals for 11 weeks.
5 is a graph showing the daily intake (a) and the dietary efficiency (b) of an experimental animal.
FIG. 6 shows the result of analyzing the serum glucose level (a) and the curve under the curve (b) of glucose during OGTT (oral glucose tolerance test).
Figure 7 shows the results of analysis of the serum glucose level (a) during the insulin resistance test and the curve backward (b) of the serum glucose during the ITT.
FIG. 8 shows the results of an analysis of bone density of the pelvis (a) and the femur (b) of an experimental animal.
FIG. 9 shows the results of measurement of lean body mass for the abdomen (a) and femur (b) of an experimental animal.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
Throughout this specification, the term "%" used hereinbelow refers to the concentration of a specific substance. Solid / solid (weight / weight)%, solid / liquid (weight / The liquid / liquid is (vol / vol)%.
Example
Experimental material
Ingredients of Mushroom
Mushroom is called cauliflower mushroom in English and its name is Sparassis crispa Wulf. : Fr. And it is the food containing the most beta - glucan among various foods. The beta-glucan contained in the mushroom is 6-branched 1,3-beta-glucan (Fig. 1), and the following structure is repeatedly linked to the dietary fiber.
Vitamin D2 and glucosyl ceramide are known to contain about 0.17 mg and 200 mg / 100 g dry weight, respectively, as other physiologically active ingredients other than beta-glucan, and Zinnia mushroom has a characteristic flavor, octanone, DL-3-octanol and 1-octene-3-ol (ol). In many cases, the content of beta-glucan contained in the mushroom is thought to be similar, but the content is actually different.
In Korea, it is grown in Hwasun and Gangwon provinces in Jeollanam-do, and the content of beta-glucan contained in them is reported to be 43.5 g / 100 g dry weight.
Example 1: Cultivation method of increasing the beta-glucan content of P. japonicus
In the present invention, the content of beta-glucan is changed according to the condition of the culture medium for growing the mushroom, and a method of containing the optimal beta-glucan is developed.
Lactobacillus was cultivated for the cultivation of mushroom cultivar. Lactobacillus was cultivated on a medium containing soybean bean and glutinous rice, Lactobacillus fermentum was used as a plant lactic acid bacteria, and Pichia kluyveri was used as a yeast. Separator ), And then adding the plant-derived lactic acid bacteria to the growth medium for the growth of the mushroom. Nutritional additives for culturing the lactic acid bacteria were prepared by mixing 80% by weight of arabinose, 15% by weight of glutinous rice and 5% by weight of rice bran.
The medium used for cultivating the mushroom was 45% by weight of sawdust, 25% by weight of rice hull, 0, 0.2, 0.4, 0.5, 0.6 and 0.7% by weight of vegetable lactic acid bacteria, . The average weight, mortality and beta-glucan content of the mushroom were measured when cultivated as a medium of Zygomycetes mushroom (Table 1).
Beta-glucan content
The content of beta - glucan was higher when the cultivated mushroom was contained in 0.4 and 0.6 wt% of lactic acid bacteria, and the mortality rate was low. In conclusion, the commercial quality and beta - glucan content of P. falciparum was highest when 0.4-0.6 wt% of vegetable lactic acid bacteria were contained in the medium.
Example 2: Animal experiment for improving the symptoms of menopausal symptoms of a composition comprising chrysanthemum mushroom as a main ingredient
Materials and methods
The ovariectomized white paper was supplied with a mixture of Lycopersicum mushroom and Lactic acid bacteria for 3 months Redness, energy, glucose, fat metabolism, and bone metabolism. The experimental design is shown in Fig. The mushroom was cultivated, harvested and cut, and then dried in a hot air dryer at a drying temperature of 55-60 ° C and a hot air velocity of 2.3 m / sec for 10 hours and then pulverized to a mesh of 200 or more. The lactic acid bacteria are Lactobacillus fermentum, (Manufactured by Wolbing LS). The lactic acid bacteria are lyophilized and powdered. Lactic acid bacteria increased the utilization rate of P. falciparum, and 0.1% of lactic acid bacteria was used in the cultivation of P. falciparum. The dietary composition was 43 energy% and the dietary fiber of the group supplemented with the mushroom powder decreased the cellulose. The composition of the dietary composition is shown in Table 2.
Relief of menopausal symptoms
A. Flushing
One symptom of menopausal symptoms is flushing, which suddenly causes fever on the face, which increases the temperature of the skin surface. To measure this in an animal, the surface temperature of the tail was measured weekly with an infrared detector at the appointed time in the afternoon.
As shown in FIG. 3A, weekly changes in body temperature of the tail skin were the highest in the control group, the normal control group was low, and the estrogen-positive control group was almost similar to the normal control group. In the case of the additive, the mushroom + Lactobacillus acidophilus group showed a significantly lower tendency than the control group, but almost the same value as the positive control group. Figure 3b is an average value for the skin temperature of the tail skin for 11 weeks.
B. Energy Ambassador
Change in body weight and body fat
Estrogen is involved in energy metabolism in the body to increase energy consumption by raising the basic metabolism, so when the lack of estrogen energy consumption is reduced and weight appears to increase. In this study, the weight gain of the control group was higher than that of the normal control group for 11 weeks, and the positive control group was significantly lower in weight gain than the control group, but significantly lower than that of the control group (FIG. Lactic acid bacteria group showed higher weight gain than control group and weight gain was significantly lower in control group than in control group. The difference in body weight was closely related to the body fat mass. The amount of EFP (epididymal fat pads) and inguinal fat (abdominal fat) were significantly higher in the control group than in the control group. But did not decrease to the level of the control group (Fig. 4B).
Energy balance
There was no difference in dietary intake between the control and control groups, and there was no difference in the diet supplemented with Mushroom and Lactobacillus (FIG. 5A). When dietary intake was divided by body weight gain, dietary efficiency was significantly higher in control and lactobacillus groups than in normal control group, and the dietary efficiency was decreased as compared with control group in normal control group. However, The diet was higher than the positive control but significantly decreased than the control (Fig. 5b). The dietary mushroom + lactic acid bacteria group had lower dietary efficiency than the mushroom group but not statistically significant (FIG. 5b). In other words, it seems to be related to the decrease of energy consumption in the control group as compared with the normal control group.
The results were the same as expected when the energy consumption was measured by indirect calorimetry, which measures oxygen consumption (VO 2 ) and carbon dioxide production (VCO 2 ) (Table 3). Energy expenditure was significantly higher in the normal control group than in the OVX white matter control group, and the estrogen-fed positive control group increased similarly to the normal control group (Table 3). Among the diets, Mushroom + Lactobacillus increased energy consumption, but did not increase as much as normal or positive control. The amount of carbohydrate burning was not different between the OVX white rats and the normal control group Sham white rats, but the fat burning amount was not significantly different between the control rats and the normal control rats , And the positive control group increased the amount of fat burning similar to that of the normal control group, and the growth of Mushroom + Lactobacillus was significantly increased compared to the control group (Table 3).
(mL / kg 0.75 / min)
(mL /
kg 0.75 / min)
kg 0.75 / min)
C. Glucose Metabolism
Changes in blood glucose and serum insulin concentrations were measured after oral administration of 2 g glucose / kg body weight every 2 months. Glucose in serum was measured by Beckman Glucose Analyzer II. Serum insulin concentrations were measured by ELISA using the Rat Insulin Specific ELISA Kit (Linco Research Inc. St. Dharles, USA). Fasting blood glucose was higher in the control group OVX white rats than in the normal control group Sham rats. All of the Oyster mushroom, Blossom mushroom, Lactobacillus acidophilus, and Lactobacillus acidophilus supplemented with OVX rats had lowering of blood glucose level and decreased to a positive control level (Table 4).
Fasting serum insulin levels were lower in the Sham white rats than in the OVX white rats. All of the mushrooms had lower serum insulin levels than those of the control group, but they were not reduced to the normal control level. However, Zygomycetes mushroom + Lactobacillus only reduced serum insulin levels to a normal control level (Table 4).
HOMA-IR, an indicator of insulin resistance, was calculated by fasting glucose and serum insulin concentrations, which means that the higher the insulin resistance, the higher the insulin resistance. HOMA-IR increased more than two fold in OVX rats as compared with Sham white rats, and decreased insulin resistance in the order of Mushroom, Mushroom, Lactobacillus, Mushroom and Lactic acid bacteria (Table 4). HOMA-B is an index of fasting insulin concentration and insulin secretion ability to calculate blood glucose, which is lower in the normal control than in the control group, indicating that the control group is insulin secreted more than necessary. HOMA-B was decreased in the positive control group similar to that of the normal control group, and the values of the mushroom and lactobacillus were similar to those of the positive control group, while the values of the mushroom + lactic acid bacteria were lower than those of the control group (Table 4).
In the oral glucose tolerance test, the peak glucose level was increased in the control group OVX rats compared to the normal control group Sham rats when the glucose level was increased after the glucose uptake and the peak glucose level was reached, and the decreasing slope was also decreased when the peak glucose level was decreased (Fig. On the OVX white paper, the positive control, Mushroom + Lactobacillus showed a peak value similar to that of the normal control group, and the area under the curve (AUC) was also lower in the first part of the oral glucose tolerance curve, 0-45 minutes . The AUC of the second part of the oral glucose tolerance test curve was lower than that of the control group, and the positive control group, the blossom mushroom + lactic acid bacterium was lower than that of the normal control group, and the AUC of the second part of the mushroom group and lactic acid bacteria was also lower than that of the control group 6b). The insulin tolerance test (ITT), which indicates the degree of insulin resistance, injected insulin at 0.75 IU insulin / kg BW without meal for 6 hours. Before starting, blood glucose was also higher in the control OVX rats than in the normal control group Sham white rats. The insulin infusion slowed blood glucose decline and the lowest blood glucose level was higher. In the positive control group, the blood sugar decline was slower (Fig. 7A). In the OVX rats, the administration of Zygomycetes mushroom + Lactobacillus showed similar blood glucose changes in the 1st and 2nd parts as in the normal control group, and the affinity for the insulin was similar to that of the normal control group (Fig. 7b). The insulin sensitivity of lactic acid bacteria was also improved compared to the OVX white paper, but lower than that of the mushroom + lactic acid bacteria (Fig. 7b). As a result, in the OVX rats, the insulin resistance involved in the regulation of blood glucose is increased and the insulin secretion is increased to overcome it, but the insulin resistance is not overcome and the blood sugar seems to be regulated higher than normal. In the OVX white paper, it was found that the administration of Mushroom + Lactic acid bacteria normalized the blood glucose control to a similar level as the positive control estrogen.
D. Lipid metabolism
Compared with the normal control group Sham white paper, the control group, OVX white rats, showed that serum total cholesterol, LDL cholesterol and HDL cholesterol levels were low (Table 5). The positive control with estrogen normalized serum lipid levels, but HDL cholesterol did not increase as normal controls. The concentrations of HDL-cholesterol were almost the same as those of the control group, and the concentration of serum triglyceride was also decreased (Table 5). However, serum LDL cholesterol levels were similar to those of the control group. In conclusion, serum lipid metabolism shows the most effective improvement in the OVX white rats when administered with Mushroom + Lactobacillus.
E. Bone mineral density and muscle mass
Bone mineral density (BMD) of the spine, right femur and tibia was measured at 4, 8, and 16 weeks after surgery and ovariectomy using bone mineral density meter (PIXIMUSTM, Lunar, USA) . After OVX surgery and diet, BMD of the pelvis was decreased compared to the normal control, estrogen administration showed almost the same BMD as the normal control group, and the growth of Mushroom + Lactobacillus was also higher than that of Mushroom or Lactobacillus 8a).
The BMD of the femur was slightly different from that of the pelvis. The BMD of the control group was significantly higher than that of the control group, and the BMD of the control group was not increased as compared with that of the control group. ). The amount of lean body mass in the pelvis and abdomen was higher than that of the control group, whereas that of the control group and the control group was higher than that of the control group (Fig. 9A). The femur also showed the same results as the pelvic region. In particular, the content of LBM was increased together with the positive control group of Brassica mushroom + Lactobacillus (Fig. 9B).
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (11)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150124824A KR101771692B1 (en) | 2015-09-03 | 2015-09-03 | Composition for Preventing, Treating or Improving Menopausal Syndrome comprising Sparassis crispa Wulf.: Fr. and Lactic Acid Bacteria as Active Ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150124824A KR101771692B1 (en) | 2015-09-03 | 2015-09-03 | Composition for Preventing, Treating or Improving Menopausal Syndrome comprising Sparassis crispa Wulf.: Fr. and Lactic Acid Bacteria as Active Ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170028486A KR20170028486A (en) | 2017-03-14 |
| KR101771692B1 true KR101771692B1 (en) | 2017-08-29 |
Family
ID=58460122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150124824A KR101771692B1 (en) | 2015-09-03 | 2015-09-03 | Composition for Preventing, Treating or Improving Menopausal Syndrome comprising Sparassis crispa Wulf.: Fr. and Lactic Acid Bacteria as Active Ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101771692B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102587940B1 (en) | 2023-03-02 | 2023-10-11 | 주식회사 현대바이오랜드 | Bifidobacterium breve HDB7040 strain for preventing or treating female menopausal syndrome via estrogen receptor-beta specific activation |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101847497B1 (en) * | 2017-03-23 | 2018-04-10 | 우혜진 | Pharmaceutical composition for preventing or treating of gynecologic disorders comprising extract of sarcodon asparatus as an ative ingredient |
| KR20200049999A (en) * | 2018-10-30 | 2020-05-11 | 주식회사 종근당바이오 | Composition for Preventing or Treating Secondary Osteoporosis Comprising Probiotics |
| KR102050063B1 (en) * | 2019-02-21 | 2019-11-28 | 덕성여자대학교 산학협력단 | COMPOSITION CONTAINING Spraciss crispa EXTRACT FOR PREVENTING OR TREATING DYSLIPIDEMIA-ASSOCIATED DISEASES |
| KR102317304B1 (en) * | 2019-05-14 | 2021-10-26 | 한국식품연구원 | Composition for preventing, improving, or treating of hypersensitivity, ant hallucination, insomnia, dizziness, or tiredness of menopausal female comprising Lactobacillus acidophilus |
| KR20200131658A (en) * | 2019-05-14 | 2020-11-24 | 한국식품연구원 | Composition for preventing, improving, or treating of arthromyalgia, headache, or colpoxerosis of menopausal female comprising Lactobacillus acidophilus |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004350621A (en) | 2003-05-30 | 2004-12-16 | Unitika Ltd | Food prepared by lactic fermentation of sparassis crispa |
-
2015
- 2015-09-03 KR KR1020150124824A patent/KR101771692B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004350621A (en) | 2003-05-30 | 2004-12-16 | Unitika Ltd | Food prepared by lactic fermentation of sparassis crispa |
Non-Patent Citations (1)
| Title |
|---|
| 갱년기초기증상, 어떻게 해결할까?. TISTORY, [Online], 2013.11.28., 인터넷 <URL: http://tstoring.tistory.com/92>* |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102587940B1 (en) | 2023-03-02 | 2023-10-11 | 주식회사 현대바이오랜드 | Bifidobacterium breve HDB7040 strain for preventing or treating female menopausal syndrome via estrogen receptor-beta specific activation |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170028486A (en) | 2017-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101771692B1 (en) | Composition for Preventing, Treating or Improving Menopausal Syndrome comprising Sparassis crispa Wulf.: Fr. and Lactic Acid Bacteria as Active Ingredient | |
| KR102130332B1 (en) | Health fuctional food composition for preventing or improving liver diseases comprising Gastrodia elata and larva | |
| KR20120002131A (en) | Composition for treating or preventing obesity containing curcuma longa extract | |
| KR101425486B1 (en) | Extract of Smilax china leaf with Aspergillus species, method for preparing the same and use of the same | |
| CN114072161A (en) | Compositions for inhibiting non-fluorescent advanced glycosylation end products and uses thereof | |
| KR20210039961A (en) | A novel anaerobic microbe isolated from human milk and method of preventing or treating metabolic disease using thereof | |
| JP2006056836A (en) | Adipose tissue-specific secreted protein production-enhancing composition | |
| JP2010083796A (en) | Cb1 receptor inhibitor | |
| JPWO2004112817A1 (en) | Celery family-derived extract and method for producing the same | |
| KR102163993B1 (en) | Weight loss-specific metabolic syndrome prevention or treatment composition using mixed grain fermentation enzyme | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| KR20130083427A (en) | Composition for preventing, improving, or treating a disease controlled by ppar action | |
| KR102037897B1 (en) | Composition for Preventing or Treating Obesity Comprising Lactic Acid Bacteria from Kefir and Grape Seed Flour | |
| JP5590758B2 (en) | Composition for regulating marker protein amount | |
| WO2018207741A1 (en) | PGC-1α BIOSYNTHESIS PROMOTER AND SLOW-TO-FAST MUSCLE CONVERSION INHIBITOR | |
| JP6894242B2 (en) | Non-alcoholic liver disease inhibitor | |
| KR101935848B1 (en) | Food composition for improving hyperglycemia using Brassica rapa | |
| JP6273440B2 (en) | GLP-1 production promoter, DPPIV inhibitor and glucose absorption inhibitor | |
| KR101493954B1 (en) | Multifunctional soybean byproducts fermented with Aspergillus species, method for preparing the same and use of the same | |
| US9801404B2 (en) | IGF-1 production-promoting agent | |
| KR20200047939A (en) | Anti-diabetic and Anti-obese Fermented Composition Comprising Fermented Hot Pepper and Fermented Hot Pepper Paste | |
| KR101904819B1 (en) | Composition comprising Fermented Momordica charantia L. and Allium sativum L. using Amyloliquefaciens Bacillus Jis-1 for lowering blood glucose or preventing and treating diabetes mellitus | |
| KR102037898B1 (en) | Composition for Preventing or Treating Hepatic Steatosis Comprising Lactic Acid Bacteria from Kefir and Grape Seed Flour | |
| KR102261326B1 (en) | Garlic fermentation composition using weissella confusa wikim29 with superior ornithine productivity | |
| KR102242002B1 (en) | Composition for preventing or treating fatty liver disease comprising solid phase fermented red ginseng extract by cordyceps |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |